Mesa Laboratories Ownership

MLAB Stock  USD 100.86  2.27  2.30%   
The market capitalization of Mesa Laboratories is $535.48 Million. The majority of Mesa Laboratories outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mesa Laboratories to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mesa Laboratories. Please pay attention to any change in the institutional holdings of Mesa Laboratories as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
1987-06-30
Previous Quarter
5.4 M
Current Value
5.5 M
Avarage Shares Outstanding
3.9 M
Quarterly Volatility
701.1 K
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Mesa Laboratories in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Mesa Laboratories, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to 7.96, whereas Dividends Paid is forecasted to decline to about 2.3 M. As of November 21, 2024, Common Stock Shares Outstanding is expected to decline to about 4.3 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 1 M.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.

Mesa Stock Ownership Analysis

About 92.0% of the company shares are owned by institutional investors. The book value of Mesa Laboratories was now reported as 29.79. The company has Price/Earnings (P/E) ratio of 433.94. Mesa Laboratories recorded a loss per share of 45.62. The entity last dividend was issued on the 29th of November 2024. Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Mesa Labs operates under Scientific Technical Instruments classification in the United States and is traded on NASDAQ Exchange. It employs 681 people. To find out more about Mesa Laboratories contact the company at 303 987 8000 or learn more at https://www.mesalabs.com.
Besides selling stocks to institutional investors, Mesa Laboratories also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Mesa Laboratories' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Mesa Laboratories' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Mesa Laboratories Quarterly Liabilities And Stockholders Equity

454.1 Million

Mesa Laboratories Insider Trades History

About 6.0% of Mesa Laboratories are currently held by insiders. Unlike Mesa Laboratories' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Mesa Laboratories' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Mesa Laboratories' insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Mesa Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mesa Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesa Laboratories backward and forwards among themselves. Mesa Laboratories' institutional investor refers to the entity that pools money to purchase Mesa Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Hhg Plc2024-06-30
114 K
Glenmede Trust Co Na2024-06-30
98.8 K
Northern Trust Corp2024-09-30
92 K
Raymond James & Associates2024-09-30
76.9 K
Kennedy Capital Management Inc2024-06-30
70.4 K
Charles Schwab Investment Management Inc2024-09-30
62.6 K
Acadian Asset Management Llc2024-06-30
59.8 K
Bank Of New York Mellon Corp2024-06-30
58.6 K
Granahan Investment Management Inc..2024-06-30
54.4 K
Blackrock Inc2024-06-30
803.5 K
Conestoga Capital Advisors, Llc2024-09-30
529.1 K
Note, although Mesa Laboratories' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mesa Laboratories Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mesa Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mesa Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mesa Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Gary Owens over three weeks ago
Disposition of 2551 shares by Gary Owens of Mesa Laboratories at 111.976 subject to Rule 16b-3
 
Gary Owens over three weeks ago
Acquisition by Gary Owens of 11559 shares of Mesa Laboratories subject to Rule 16b-3
 
Brian Archbold over two months ago
Disposition of 1499 shares by Brian Archbold of Mesa Laboratories at 125.0 subject to Rule 16b-3
 
Sullivan John James over two months ago
Acquisition by Sullivan John James of 1074 shares of Mesa Laboratories subject to Rule 16b-3
 
Alltoft Jennifer Sadie over two months ago
Disposition of 1074 shares by Alltoft Jennifer Sadie of Mesa Laboratories subject to Rule 16b-3
 
Capone Mark Christopher over three months ago
Disposition of 724 shares by Capone Mark Christopher of Mesa Laboratories subject to Rule 16b-3
 
John Sakys over three months ago
Acquisition by John Sakys of 8351 shares of Mesa Laboratories subject to Rule 16b-3
 
Brian Archbold over three months ago
Acquisition by Brian Archbold of 889 shares of Mesa Laboratories subject to Rule 16b-3
 
Gary Owens over three months ago
Disposition of 1000 shares by Gary Owens of Mesa Laboratories subject to Rule 16b-3
 
John Sakys over three months ago
Disposition of 511 shares by John Sakys of Mesa Laboratories subject to Rule 16b-3
 
Brian Archbold over six months ago
Disposition of 420 shares by Brian Archbold of Mesa Laboratories at 142.4 subject to Rule 16b-3
 
Capone Mark Christopher over six months ago
Acquisition by Capone Mark Christopher of 724 shares of Mesa Laboratories subject to Rule 16b-3

Mesa Laboratories Outstanding Bonds

Mesa Laboratories issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mesa Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mesa bonds can be classified according to their maturity, which is the date when Mesa Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Mesa Laboratories Corporate Filings

8K
7th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
29th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
15th of October 2024
An amended filing to the original Schedule 13G
ViewVerify
19th of July 2024
Other Reports
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Mesa Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesa Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesa Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesa Laboratories Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
3.875
Dividend Share
0.64
Earnings Share
(45.62)
Revenue Per Share
42.3
Quarterly Revenue Growth
0.088
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.